Mallinckrodt to sell nuclear imaging business to IBAM for $690 million

24 August 2016
mergers-acquisitions-big

US specialty pharmaceutical company Mallinckrodt (NYSE: MNK) saw its shares rise more than 2% to $86.06 in pre-market trading, after announcing that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM).

The total consideration of around $690 million (before tax impacts) consists of about $574 million of up-front consideration, the assumption of around $39 million of long-term obligations, and about $77 million of contingent consideration.

"Mallinckrodt's Nuclear Imaging operation has a long history going back 50 years, and has been a strong cash-generating business over time. Our team has made significant progress in driving profitability over the past few years," said Mark Trudeau, president and chief executive of Mallinckrodt.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics